{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-25-000067","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.640707+00:00","generated_at":"2026-05-17T15:47:38.184618+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biohaven reports Q2 net loss $198M, cash $408.2M; OCD trial fails, VYGLXIA PDUFA in Q4 2025","bullets":["Net loss of $198.1M ($1.94 per share) vs $319.8M in Q2 2024; no revenue, clinical-stage biopharma.","Cash, equivalents and marketable securities $408.2M as of June 30, 2025.","Phase 3 OCD trial with troriluzole showed no efficacy signal; program terminated.","VYGLXIA NDA for spinocerebellar ataxia under priority review, PDUFA in Q4 2025.","Early clinical data: BHV-1300 IgG reductions up to 87%, BHV-1510 ADC showed tumor reduction in first 6/6 patients with cemiplimab."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-25-000067","json":"https://secwatch.observer/filing/0001935979-25-000067.json","markdown":"https://secwatch.observer/filing/0001935979-25-000067.md","text":"https://secwatch.observer/filing/0001935979-25-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/0001935979-25-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/bhvn-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:47:38.184618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}